Correlation Between Emergent Biosolutions and Takeda Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Emergent Biosolutions and Takeda Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Emergent Biosolutions and Takeda Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Emergent Biosolutions and Takeda Pharmaceutical Co, you can compare the effects of market volatilities on Emergent Biosolutions and Takeda Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Emergent Biosolutions with a short position of Takeda Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Emergent Biosolutions and Takeda Pharmaceutical.

Diversification Opportunities for Emergent Biosolutions and Takeda Pharmaceutical

-0.5
  Correlation Coefficient

Very good diversification

The 3 months correlation between Emergent and Takeda is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Emergent Biosolutions and Takeda Pharmaceutical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Takeda Pharmaceutical and Emergent Biosolutions is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Emergent Biosolutions are associated (or correlated) with Takeda Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Takeda Pharmaceutical has no effect on the direction of Emergent Biosolutions i.e., Emergent Biosolutions and Takeda Pharmaceutical go up and down completely randomly.

Pair Corralation between Emergent Biosolutions and Takeda Pharmaceutical

Considering the 90-day investment horizon Emergent Biosolutions is expected to generate 8.31 times more return on investment than Takeda Pharmaceutical. However, Emergent Biosolutions is 8.31 times more volatile than Takeda Pharmaceutical Co. It trades about 0.05 of its potential returns per unit of risk. Takeda Pharmaceutical Co is currently generating about -0.02 per unit of risk. If you would invest  791.00  in Emergent Biosolutions on August 27, 2024 and sell it today you would earn a total of  157.00  from holding Emergent Biosolutions or generate 19.85% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Emergent Biosolutions  vs.  Takeda Pharmaceutical Co

 Performance 
       Timeline  
Emergent Biosolutions 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point.
Takeda Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Takeda Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Emergent Biosolutions and Takeda Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Emergent Biosolutions and Takeda Pharmaceutical

The main advantage of trading using opposite Emergent Biosolutions and Takeda Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Emergent Biosolutions position performs unexpectedly, Takeda Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will offset losses from the drop in Takeda Pharmaceutical's long position.
The idea behind Emergent Biosolutions and Takeda Pharmaceutical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities